Financing ·
On August 13, 2026, Optimi Health Corp. entered into a common shares purchase agreement with Seven Knots, LLC…
OPTHOptimi Health Corp.
On August 13, 2026, Optimi Health Corp. entered into a common shares purchase agreement with Seven Knots, LLC, establishing an equity line of credit allowing the Company to sell up to US$100 million of its common shares at its discretion. The facility permits draws of up to US$2 million per transaction, priced at 97% of the lower of the daily low or volume-weighted average price, subject to a floor equal to 85% of the prior day's closing price. To secure Seven Knots' commitment, Optimi issued an unsecured convertible promissory note with a principal amount of US$1.5 million and agreed to issue a second note for US$0.5 million if gross proceeds exceed US$7 million. These notes mature in 24 months and are convertible at 95% of the 20-day VWAP, subject to a $3.00 floor price. Joseph Gunnar & Co. LLC serves as the exclusive placement agent, entitled to a 3% fee on gross proceeds. Optimi Health Corp. is a commercial-stage pharmaceutical manufacturer specializing in regulated psychedelic drug products for mental health therapies.